Rational management of posttransplant lymphoproliferative disorder in pediatric recipients

Kartik Praghakaran, Barbara Wise, Allen Chen, Kathleen Schwarz, Paul Colombani

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Purpose: Posttransplant lymphoproliferative disorder (PTLD) is a potentially lethal complication in the pediatric transplant patient secondary to Epstein-Barr virus (EBV) infection and potent immunosuppression. PTLD may develop in up to 10% of pediatric transplant recipients with mortality rates up to 80%. The authors report their experience with the diagnosis and efficacy of aggressive sequential management of PTLD in five patients under age 5 years. Methods: A review of 75 pediatric liver transplant recipients on FK-506-based immunosuppression identified five biopsyproven cases of PTLD and one probable case (8%). The probable case was a teenager, 6 months posttransplant in Spain, with mediastinal masses. No treatment or diagnosis was sought, and the patient died. The other five cases were managed with sequential therapy on an 'intent-to-treat' basis with initial withdrawal of immunosuppression. If the disease progressed, patients were treated with four courses of intravenous cyclophosphamide, vincristine, Adriamycin, and intrathecal methotrexate and ara-C. Results: Five children were anti-EBV titer negative at the time of transplant. Three of five received EBV-positive donor organs and two children received EBV-negative livers. Monoclonal PTLD developed between 2 and 31 months posttransplant (mean, 15.7 months). With onset of PTLD (four B cell lymphoma, one B cell leukemia) all patients had tapering or withdrawal of immunosuppression and initiation of highdose acyclovir. Two of five patients had complete remission and resumed immunosuppression. Two patients-progressed and required chemotherapy. One patient with initial response relapsed 4 months later with B cell leukemia and required chemotherapy. All five patients are alive 10 to 38 months postdiagnosis (mean, 29 months). Three patient's had rejection requiring resumption of FK-506 therapy. Two patients are maintained on low- dose alternate-day prednisone and no FK-506. All patients have normal liver function. Central nervous system lymphoma developed in one child With significant neurological sequelae. Conclusions: PTLD can develop in pediatric liver transplant recipients. Early withdrawal of immunosuppression and aggressive chemotherapy enabled us to achieve 100% patient and graft survival.

Original languageEnglish (US)
Pages (from-to)112-116
Number of pages5
JournalJournal of pediatric surgery
Volume34
Issue number1
DOIs
StatePublished - Jan 1999

Keywords

  • B cell lymphoma
  • Pediatric liver transplant
  • Posttransplant lymphoproliferative disorder

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Rational management of posttransplant lymphoproliferative disorder in pediatric recipients'. Together they form a unique fingerprint.

Cite this